NLE Psychiatric Disorders — Schizophrenia and Psychotic DisordersDetailed Explanation

Understanding Psychosis and Schizophrenia Spectrum Disorders

Psychosis is a clinical state characterized by a loss of contact with reality. The person can no longer reliably distinguish between what is real and what is not, leading to disturbances in thought content, thought process, sensory perception, and behavior. Schizophrenia is the most well-known and clinically severe psychotic disorder. It is defined by the presence of characteristic symptoms — including hallucinations, delusions, disorganized speech, disorganized behavior, and negative symptoms — for at least six months, with at least one month of active-phase symptoms. Onset is typically in late adolescence to early adulthood (late teens to mid-30s), and males often present earlier and more severely than females. The schizophrenia spectrum includes several related disorders that the NLE may test: 1. Schizophrenia — symptoms lasting ≥6 months including ≥1 month of active-phase symptoms. 2. Schizophreniform Disorder — same symptoms as schizophrenia but lasting 1–6 months; full recovery is possible. 3. Brief Psychotic Disorder — sudden onset of psychotic symptoms lasting less than one month, often triggered by a severe stressor (e.g., sudden death of a loved one, typhoon trauma — contexts relevant in the Philippine setting). Recovery is typically complete. 4. Schizoaffective Disorder — meets criteria for both schizophrenia and a major mood episode (major depression or bipolar). The client experiences psychotic symptoms even during periods without mood symptoms. 5. Delusional Disorder — persistent, non-bizarre delusions (beliefs that could theoretically happen, e.g., 'my neighbor is poisoning my food') without other psychotic features like disorganized speech or hallucinations. Functioning is relatively preserved. The neurobiological basis of schizophrenia centers on the dopamine hypothesis: excessive dopamine activity in the mesolimbic pathway drives positive symptoms, while reduced dopamine activity in the mesocortical pathway contributes to negative symptoms. Antipsychotic drugs exploit this by blocking D2 dopamine receptors. Serotonin also plays a role, particularly relevant to atypical antipsychotics. In the Philippine setting, RA 11036 (Mental Health Act, 2018) emphasizes that persons with schizophrenia have the right to be treated in the least restrictive setting available, often the community, and that their dignity, autonomy, and recovery must be the center of all care.

Positive and Negative Symptoms of Schizophrenia

The two-symptom domain model is fundamental to understanding schizophrenia and guides both pharmacological and nursing interventions. The key concept: positive symptoms ADD something abnormal; negative symptoms REMOVE something normal. POSITIVE SYMPTOMS (excess or distortion of normal function): Think of the word 'positive' not as 'good' but as 'something added that should not be there.' 1. Hallucinations — false sensory perceptions without a real external stimulus. The person hears, sees, smells, tastes, or feels something that is not there. In schizophrenia, AUDITORY HALLUCINATIONS (hearing voices) are the most common and most clinically important. These voices may be commenting on the person's actions, conversing with each other, or — most dangerously — giving COMMAND HALLUCINATIONS (ordering the person to harm themselves or others). This is a safety priority. 2. Delusions — fixed, false beliefs that are resistant to logic or evidence. Types include: - Persecutory (paranoid): 'The NBI is following me.' - Grandiose: 'I am the reincarnation of Rizal.' - Referential: 'The news anchor on TV is talking directly to me.' - Somatic: 'My organs are rotting inside my body.' - Thought broadcasting: 'Everyone can hear my thoughts.' - Thought insertion: 'Someone is putting thoughts into my mind.' - Thought withdrawal: 'Someone is removing my thoughts.' 3. Disorganized Speech and Thinking — includes loose associations (ideas randomly connected), tangential speech (never reaching the point), circumstantial speech (eventually reaching the point but with many irrelevant details), word salad (completely incoherent mixture of words), neologisms (made-up words), and clang associations (rhyming words without logical connection). 4. Disorganized or Bizarre Behavior — unpredictable behavior, agitation, catatonia (stupor, posturing, waxy flexibility), or inappropriate affect (laughing at sad news). NEGATIVE SYMPTOMS (loss or absence of normal function): Memorize the 5 A's: 1. Affective Flattening (Blunted/Flat Affect) — greatly reduced emotional expression; the face appears expressionless, voice is monotonous. 2. Alogia — poverty of speech; brief, empty replies to questions; 'poverty of thought.' 3. Avolition — lack of motivation and inability to initiate or sustain goal-directed activities (e.g., won't bathe, won't go to work). 4. Anhedonia — inability to experience pleasure from activities that were previously enjoyable. 5. Asociality — withdrawal from social relationships and activities. CLINICAL SIGNIFICANCE: - Positive symptoms generally RESPOND WELL to antipsychotic medications (both typical and atypical). - Negative symptoms are MORE DISABLING in the long term (they destroy daily functioning and quality of life) and RESPOND POORLY to typical antipsychotics. Atypical antipsychotics (especially clozapine, olanzapine) have greater efficacy for negative symptoms. - The nurse must assess BOTH domains at every interaction to monitor treatment effectiveness.

Therapeutic Communication: Hallucinations and Delusions

Therapeutic communication is a core nursing skill that is frequently tested on the NLE. In schizophrenia, the nurse must know EXACTLY what to say — and what NOT to say — when a client is experiencing hallucinations or delusions. Wrong communication can worsen symptoms, damage therapeutic trust, or put the client or others at risk. COMMUNICATING WITH A CLIENT EXPERIENCING HALLUCINATIONS: Step 1 — ASSESS DIRECTLY. Do not avoid the topic. Ask directly: 'Are you hearing voices right now? What are they saying?' This is especially critical to detect COMMAND HALLUCINATIONS. Never assume the voices are harmless. Step 2 — DO NOT ARGUE WITH OR REINFORCE THE HALLUCINATION. Do not say: 'There are no voices, stop imagining things' (argumentative, damages trust). Do not say: 'Oh yes, I hear them too' (reinforcing, dishonest, untherapeutic). Step 3 — ACKNOWLEDGE THE CLIENT'S EXPERIENCE AND PRESENT REALITY. Use therapeutic statements: - 'I don't hear the voices, but I understand they feel very real and frightening to you.' - 'I can see you are distressed. I am here with you.' - 'The voices you are hearing are a symptom of your illness. I am going to stay with you.' Step 4 — REDUCE STIMULATION AND REDIRECT. A busy, noisy environment worsens hallucinations. Move to a quieter area. Redirect attention to a concrete, reality-based activity (e.g., 'Let's take a walk together.'). Step 5 — TEACH COPING STRATEGIES (long-term). Clients can learn to manage hallucinations: humming, listening to music, engaging in a task, using a grounding technique (name 5 things you can see). COMMUNICATING WITH A CLIENT EXPERIENCING DELUSIONS: The two cardinal rules are: (1) DO NOT ARGUE with the delusion — arguing entrenches the belief and destroys trust; (2) DO NOT AGREE WITH (validate) the delusion — agreeing reinforces it as real and is therapeutically dishonest. The correct approach is a MIDDLE PATH: - Acknowledge the UNDERLYING FEELING, not the content of the delusion. - If a client says: 'The PNP is following me everywhere and wants to kill me,' DO NOT say: 'That's not true' (argument) or 'Oh no, that must be terrible that they're following you' (validation). - DO say: 'It must be very frightening to feel that you are in danger. You are safe here. I am your nurse, and I will not let anything harm you.' - FOCUS ON REALITY-BASED TOPICS and the therapeutic relationship. Build trust through consistency, honesty, and reliability. - DO NOT GIVE DETAILED EXPLANATIONS that feed into the delusional system (e.g., explaining security procedures when the client believes nurses are spies). - PRESENT REALITY GENTLY: 'I understand you believe that, but I don't share that belief. Let's talk about how you are feeling today.' GENERAL COMMUNICATION PRINCIPLES FOR PSYCHOTIC CLIENTS: - Use CLEAR, SIMPLE, CONCRETE language. Avoid metaphors, idioms, and abstract concepts (e.g., don't say 'You'll feel under the weather tomorrow' — this can be misinterpreted). - Speak SLOWLY and CALMLY. Maintain a calm tone and demeanor even if the client is agitated. - OFFER BRIEF, FREQUENT CONTACTS rather than long, demanding interactions, especially for withdrawn clients. - Do NOT insist on direct eye contact or physical closeness — this can feel threatening to a paranoid client. - Be CONSISTENT: same nurse, same schedule, same boundaries build therapeutic trust. - Maintain SAFETY AWARENESS at all times — stand near the door, observe body language, and keep the environment free of dangerous objects.

Antipsychotic Pharmacology: Typical vs. Atypical

Antipsychotics (also called neuroleptics) are the cornerstone of pharmacological treatment for schizophrenia. They work primarily by BLOCKING DOPAMINE D2 RECEPTORS in the brain. The NLE tests this topic heavily, particularly the differences between the two generations of antipsychotics and their respective side effect profiles. TYPICAL (FIRST-GENERATION) ANTIPSYCHOTICS: Key drugs: HALOPERIDOL (Haldol), CHLORPROMAZINE (Thorazine), FLUPHENAZINE (Prolixin), PERPHENAZINE, THIORIDAZINE. Mechanism: STRONG D2 blockade. This strong dopamine blockade explains their efficacy for POSITIVE SYMPTOMS but also their HIGH RISK OF EPS (extrapyramidal side effects), because D2 blockade in the motor (nigrostriatal) pathway disrupts movement control. Potency matters: - HIGH-POTENCY typicals (haloperidol, fluphenazine) → MORE EPS, less sedation, less anticholinergic, less hypotension. - LOW-POTENCY typicals (chlorpromazine) → LESS EPS but MORE sedation, MORE anticholinergic effects (dry mouth, constipation, urinary retention, blurred vision), MORE orthostatic hypotension. Long-acting depot injections: HALOPERIDOL DECANOATE (monthly IM) and FLUPHENAZINE DECANOATE (every 2–4 weeks IM) are available and are extremely useful in the Philippine community setting for clients with poor medication adherence — a major cause of relapse. ATYPICAL (SECOND-GENERATION) ANTIPSYCHOTICS: Key drugs: RISPERIDONE (Risperdal), OLANZAPINE (Zyprexa), QUETIAPINE (Seroquel), CLOZAPINE (Clozaril), ARIPIPRAZOLE (Abilify), ZIPRASIDONE, PALIPERIDONE. Mechanism: Block D2 receptors AND SEROTONIN (5-HT2A) receptors. The serotonin antagonism is thought to reduce EPS and improve efficacy for negative symptoms. Advantages over typicals: 1. Effective for BOTH positive AND NEGATIVE symptoms — a major advantage. 2. FEWER EPS (though not zero — risperidone at high doses can cause EPS). Disadvantages — METABOLIC SYNDROME: The major drawback of atypicals is METABOLIC SIDE EFFECTS: - Weight gain (especially olanzapine and clozapine) - Hyperglycemia / new-onset Type 2 Diabetes - Dyslipidemia (elevated triglycerides, LDL) Monitor: weight, BMI, fasting blood glucose, and lipid profile at baseline and regularly. OLANZAPINE and CLOZAPINE cause the most severe metabolic effects. SPECIAL CASES: - CLOZAPINE: Most effective antipsychotic (especially for treatment-resistant schizophrenia and suicidality) but reserved for when 2+ other antipsychotics have failed due to AGRANULOCYTOSIS risk — covered in detail in the Clozapine section. - ARIPIPRAZOLE: A partial D2 AGONIST — unique mechanism; generally weight-neutral, minimal metabolic effects. - RISPERIDONE: Causes HYPERPROLACTINEMIA (elevated prolactin) — more than other atypicals — leading to galactorrhea (breast milk discharge), menstrual irregularities, and sexual dysfunction. GENERAL ANTIPSYCHOTIC SIDE EFFECTS (applicable to both classes): - Orthostatic hypotension (especially low-potency typicals and some atypicals): Teach the client to RISE SLOWLY from lying/sitting to prevent falls. - Sedation: Especially chlorpromazine, quetiapine, olanzapine. - Photosensitivity: Use sunscreen and protective clothing (IMPORTANT in the Philippines — a tropical country with intense sun exposure). Chlorpromazine can also cause a gray-blue skin discoloration (rare) with prolonged sun exposure. - Anticholinergic effects: Dry mouth, blurred vision, constipation, urinary retention, tachycardia. More prominent with low-potency typicals. - Lowered seizure threshold: Especially clozapine. - Hyperprolactinemia: Especially with typicals and risperidone — causes galactorrhea, amenorrhea, sexual dysfunction, and long-term bone loss. MEDICATION ADHERENCE: The MOST COMMON cause of relapse in schizophrenia is STOPPING MEDICATION. The nurse must emphasize that antipsychotics must be taken continuously even when the client feels well. Long-acting depot injections are a highly effective adherence tool.

Extrapyramidal Side Effects (EPS)

EPS are movement disorders caused by dopamine D2 blockade in the NIGROSTRIATAL PATHWAY (the brain's motor control circuit). They are among the most tested pharmacological complications in NLE psychiatric nursing questions. You MUST know each type by its TIMING, PRESENTATION, and MANAGEMENT. There are FOUR main types of EPS: 1. ACUTE DYSTONIA Onset: EARLY — within HOURS to DAYS of starting or increasing the antipsychotic dose. Presentation: Sudden, sustained, PAINFUL MUSCLE SPASMS typically involving the neck, face, jaw, tongue, and eyes. - TORTICOLLIS: Twisted, rigid neck, head pulled to one side. - OCULOGYRIC CRISIS: Eyes roll upward and become fixed — looks alarming. - LARYNGEAL/PHARYNGEAL DYSTONIA: Spasm of throat muscles — this can obstruct the airway and is a MEDICAL EMERGENCY requiring immediate intervention. The client is often terrified. Treatment: IMMEDIATE IM or IV ANTICHOLINERGIC — BENZTROPINE (Cogentin) or DIPHENHYDRAMINE (Benadryl). These work rapidly and dramatically relieve the spasm. 2. AKATHISIA Onset: Within DAYS to WEEKS. Presentation: Subjective feeling of motor RESTLESSNESS — the client cannot sit still, must keep moving, paces constantly, shifts weight, has inner tension described as 'I feel like I want to jump out of my skin.' It is often mistaken for worsening anxiety or psychotic agitation — a critical NLE distinction. Treatment: Reduce antipsychotic dose; PROPRANOLOL (beta-blocker) — first-line pharmacological management; benzodiazepines (lorazepam); diphenhydramine or benztropine (less effective for akathisia than for other EPS). 3. PSEUDOPARKINSONISM (Drug-Induced Parkinsonism) Onset: Within DAYS to WEEKS. Presentation: Resembles idiopathic Parkinson's disease: - TREMOR (pill-rolling, at rest) - RIGIDITY (cogwheel rigidity — a ratcheting resistance felt when moving the client's arm) - BRADYKINESIA (slowed movement) - MASK-LIKE FACE (reduced facial expression) - SHUFFLING GAIT (small, slow steps) - DROOLING - Stooped posture Treatment: ANTICHOLINERGICS — BENZTROPINE (Cogentin) or TRIHEXYPHENIDYL (Artane); AMANTADINE. 4. TARDIVE DYSKINESIA (TD) Onset: LATE — months to YEARS of antipsychotic use. The word 'tardive' means 'late-appearing.' Presentation: INVOLUNTARY, REPETITIVE MOVEMENTS, predominantly of the face, mouth, and tongue: - Lip-smacking - Chewing movements - Tongue protrusion (tongue flicking or rolling) - Facial grimacing - Choreiform (writhing) movements of the limbs and trunk These movements are OFTEN IRREVERSIBLE — even after stopping the drug. Treatment: NO reliable treatment. KEY NURSING ACTIONS: - Prevention: Use the LOWEST effective antipsychotic dose; minimize duration of exposure. - EARLY DETECTION: Assess regularly using the Abnormal Involuntary Movement Scale (AIMS). - If TD appears: Reduce the dose or SWITCH to an atypical antipsychotic (atypicals carry lower TD risk). - CRITICAL: ANTICHOLINERGICS DO NOT HELP TD AND MAY ACTUALLY WORSEN IT. This is a classic NLE trap. ANTICHOLINERGIC MANAGEMENT OF EPS: Agents: BENZTROPINE (Cogentin), TRIHEXYPHENIDYL (Artane), DIPHENHYDRAMINE (Benadryl). Useful for: Acute dystonia ✓, Pseudoparkinsonism ✓, Akathisia (partially) ✓. NOT useful for: Tardive Dyskinesia ✗ (may worsen). Anticholinergic side effects to teach: - Dry mouth: Sugar-free candies, frequent sips of water. - Blurred vision: Caution with driving or activities requiring sharp vision. - Constipation: High-fiber diet, increased fluid intake. - Urinary retention: Monitor for difficulty urinating; report to physician. - Impaired sweating (anhidrosis): HIGH RISK OF HEAT STROKE — critical warning in tropical Philippines. Advise clients to stay in cool environments, use electric fans, drink adequate fluids.

Neuroleptic Malignant Syndrome (NMS): A Psychiatric Emergency

Neuroleptic Malignant Syndrome (NMS) is a RARE BUT LIFE-THREATENING idiosyncratic reaction to antipsychotic medications. It is one of the MOST IMPORTANT MEDICAL EMERGENCIES in psychiatric nursing and is consistently tested on the NLE. The nurse must recognize it IMMEDIATELY because delayed treatment can be fatal. CAUSES: NMS can occur with ANY antipsychotic medication, but it is most commonly associated with HIGH-POTENCY TYPICAL ANTIPSYCHOTICS (especially haloperidol, fluphenazine). It can also occur with atypical antipsychotics. It may be triggered by rapid dose increases, high doses, intramuscular administration, or occurs spontaneously. Dehydration and physical exhaustion are predisposing factors. PATHOPHYSIOLOGY: Massive, sudden blockade of dopamine receptors throughout the brain causes failure of temperature regulation (hyperthermia), severe motor rigidity (from nigrostriatal blockade), and autonomic dysregulation. THE FOUR CARDINAL FEATURES (memorize ALL four): 1. HYPERTHERMIA — HIGH FEVER, typically >38–40°C. This is central to NMS. The temperature can reach dangerous levels (>41°C in severe cases). 2. SEVERE MUSCLE RIGIDITY — Classic description is 'LEAD-PIPE RIGIDITY' — the muscles are uniformly, intensely rigid. This is NOT the cogwheel rigidity of pseudoparkinsonism — it is extreme, 'pipe-like' resistance throughout the limb. 3. AUTONOMIC INSTABILITY — Fluctuating or labile blood pressure, tachycardia, diaphoresis (profuse sweating), tachypnea, and pallor or flushing. The autonomic nervous system is completely dysregulated. 4. ALTERED MENTAL STATUS — Confusion, agitation, stupor, fluctuating consciousness, possibly coma. LABORATORY FINDINGS: - Markedly ELEVATED CREATINE KINASE (CK) — from massive muscle breakdown (rhabdomyolysis). CK levels may reach thousands of units per liter (normal is ~20–200 U/L). - LEUKOCYTOSIS (elevated WBC) — inflammatory response. - Elevated creatinine / BUN — rhabdomyolysis can precipitate ACUTE KIDNEY INJURY (myoglobin from muscle breakdown blocks the renal tubules). - Elevated liver enzymes. PRIORITY MANAGEMENT — FIVE KEY ACTIONS: 1. STOP THE ANTIPSYCHOTIC IMMEDIATELY — this is the single most important intervention. 2. AGGRESSIVE COOLING for hyperthermia — cooling blankets, ice packs to axillae, groin, and neck, cool IV fluids. Monitor temperature continuously. 3. IV FLUIDS AND HYDRATION — to maintain renal perfusion, prevent acute kidney injury from rhabdomyolysis. 4. DANTROLENE (muscle relaxant) — reduces rigidity and heat production by preventing calcium release in muscle cells. This is the specific pharmacological treatment for NMS. 5. BROMOCRIPTINE (dopamine agonist) — counteracts the dopamine blockade that drives NMS. Additional: Cardiovascular and respiratory support, ICU monitoring, seizure precautions. DISTINGUISHING NMS FROM SEROTONIN SYNDROME: This is a CLASSIC NLE TRAP — both cause hyperthermia and autonomic instability, but they differ in: - DRUG: NMS → ANTIPSYCHOTICS (dopamine blockers). Serotonin Syndrome → SEROTONERGIC drugs (SSRIs, SNRIs, MAOIs, tramadol, linezolid, triptans). - NEUROMUSCULAR SIGN: NMS → LEAD-PIPE RIGIDITY. Serotonin Syndrome → HYPERREFLEXIA and CLONUS (rhythmic, involuntary muscle contractions when the tendon is stretched) — not rigidity. - ONSET: Serotonin syndrome tends to have faster onset (within 24 hours of drug change). - Treatment: NMS → dantrolene, bromocriptine. Serotonin syndrome → cyproheptadine (serotonin antagonist), benzodiazepines.

Clozapine and Agranulocytosis: Special Safety Considerations

Clozapine (Clozaril) occupies a unique position in psychiatry: it is the MOST EFFECTIVE antipsychotic available — particularly for treatment-resistant schizophrenia (schizophrenia that has failed at least two other adequate antipsychotic trials) and for reducing suicidal behavior in schizophrenia. However, it comes with a BLACK-BOX WARNING for AGRANULOCYTOSIS — a potentially fatal drop in white blood cells — which requires intensive monitoring and makes it a HIGH-PRIORITY NLE TOPIC. WHAT IS AGRANULOCYTOSIS? Agranulocytosis is a severe decrease in GRANULOCYTES, particularly NEUTROPHILS — the white blood cells responsible for fighting bacterial infections. When neutrophils drop to dangerously low levels (Absolute Neutrophil Count <500 cells/mm³), the client becomes susceptible to overwhelming, life-threatening infections that the body cannot fight. This can develop rapidly and progress to sepsis and death if undetected. CLOZAPINE-SPECIFIC MONITORING PROTOCOL: Because of this risk, clozapine can ONLY be prescribed, dispensed, and administered under a strict monitoring program: - BASELINE: WBC and ANC BEFORE starting clozapine. - WEEKLY monitoring of WBC and ANC for the FIRST 6 MONTHS. - BIWEEKLY (every 2 weeks) monitoring from months 6–12 if counts remain stable. - MONTHLY monitoring after 12 months if counts remain stable. - If the WBC falls to <3,000/mm³ or ANC falls to <1,500/mm³: INTERRUPT clozapine and monitor closely. - If WBC <2,000/mm³ or ANC <1,000/mm³: DISCONTINUE clozapine PERMANENTLY. Clozapine cannot be restarted in a patient who has developed agranulocytosis. NURSING TEACHING — SIGNS OF AGRANULOCYTOSIS: The client MUST know to REPORT IMMEDIATELY: - FEVER - SORE THROAT - MOUTH ULCERS (mouth sores) - FLU-LIKE SYMPTOMS (chills, malaise, weakness) These symptoms may signal agranulocytosis, and the client must seek immediate medical attention — do not wait, do not assume it is a common cold. OTHER IMPORTANT CLOZAPINE SIDE EFFECTS: 1. SEIZURES — Clozapine LOWERS THE SEIZURE THRESHOLD significantly, especially at high doses. The client should be on seizure precautions, and antiepileptic drugs may be co-prescribed at higher doses. 2. MYOCARDITIS — Inflammation of the heart muscle, most often in the first month of therapy. Monitor for chest pain, palpitations, shortness of breath, fever, and fatigue — especially in the first 4–8 weeks. 3. SEVERE METABOLIC EFFECTS — Among the worst of all antipsychotics for weight gain, hyperglycemia, and dyslipidemia. Intensive metabolic monitoring and lifestyle counseling are needed. 4. SEVERE CONSTIPATION — Clozapine's strong anticholinergic effects cause severe constipation that can progress to paralytic ileus and fecal impaction — a potentially life-threatening complication. Monitor bowel function at every visit; prescribe a bowel regimen (stool softeners, high-fiber diet, adequate fluids) prophylactically. 5. SIALORRHEA (drooling) — Excessive saliva production; paradoxical given its anticholinergic properties. 6. SEDATION — Significant, especially at higher doses. 7. ORTHOSTATIC HYPOTENSION — Especially early in treatment. 8. MINIMAL EPS — One of clozapine's advantages is very low EPS and very low TD risk. NURSING ROLE: The nurse plays a critical role in ensuring WBC/ANC monitoring compliance, educating the client about infection warning signs, maintaining the monitoring schedule, and communicating lab results to the prescribing physician. In the Philippines, where access to laboratory services may be limited in rural areas, nurses must assist clients in navigating healthcare systems to ensure this monitoring occurs.

Acute dystonia is the EARLIEST EPS manifestation (hours to days). High-potency typical antipsychotics like haloperidol cause the highest EPS risk. Torticollis (twisted neck) and oculogyric crisis (eyes rolled upward) are classic acute dystonic reactions. The nurse must: (1) Stay with the client, reassure him, and call for help. (2) Notify the physician immediately. (3) Administer IM/IV benztropine 1–2 mg or diphenhydramine 25–50 mg as ordered. Response is rapid — within minutes. (4) CRITICAL: Assess for laryngeal involvement (stridor, difficulty breathing, voice change) — laryngeal dystonia is an AIRWAY EMERGENCY requiring immediate escalation. (5) Document the reaction, the drug dose and timing, and the treatment administered. The physician will likely discuss switching to an atypical antipsychotic to reduce future EPS risk.

Olanzapine (and clozapine) carry the highest metabolic side effect risk among atypical antipsychotics. The 'three S's' — polydipsia (thirst), polyuria, and unexplained weight gain — are classic signs of new-onset diabetes. Nursing actions: (1) Report the blood glucose and symptoms to the physician immediately. (2) Anticipate orders for fasting blood glucose and HbA1c to confirm diabetes. (3) Obtain a full metabolic panel: lipid profile, liver function, kidney function. (4) Collaborate with the physician regarding medication review — a switch to a metabolically neutral agent (e.g., aripiprazole, ziprasidone) may be considered. (5) Provide dietary and lifestyle counseling: low-sugar, low-fat diet; regular physical activity; weight management. (6) Educate the client about diabetes self-management. (7) Stress that the antipsychotic should NOT be stopped without physician guidance, even though it is causing metabolic problems — psychiatric relapse is dangerous. (8) Refer to an endocrinologist or internist for diabetes management. Nursing diagnosis: Imbalanced Nutrition: More Than Body Requirements; Risk for Unstable Blood Glucose Level; Deficient Knowledge.

This client is experiencing a paranoid delusion (tracking device) and thought broadcasting (thoughts being transmitted). The nurse's response should: (1) NOT argue: Do NOT say 'That is impossible — there's no device in your brain.' (2) NOT agree: Do NOT say 'That sounds terrible that they're monitoring you.' (3) USE THE CORRECT APPROACH: 'It sounds like you are feeling very unsafe and that people around you cannot be trusted. That must be very distressing. I want you to know that I am your nurse, and my only purpose here is to help you. I am not here to monitor or harm you.' (4) Redirect to concrete reality: 'You are safe here. Let's talk about how you have been feeling and how your medication has been helping you.' (5) Build therapeutic trust through consistency and honesty. NANDA Diagnoses: Disturbed Thought Processes related to psychiatric disorder, evidenced by paranoid delusions and thought broadcasting; Social Isolation related to paranoid ideation; Risk for Other-Directed Violence related to paranoid delusions (assess potential for aggression toward perceived 'surveillance agents'). Prioritize safety assessment first (Maslow: safety).

TD characteristically appears after months to years of antipsychotic use and predominantly affects the face, mouth, and tongue (lip-smacking, chewing, tongue protrusion, grimacing). The client often lacks awareness of the movements. Nursing actions: (1) Report the findings to the psychiatrist immediately. (2) Perform a formal AIMS (Abnormal Involuntary Movement Scale) assessment and document the score. (3) CRITICAL: Do NOT administer anticholinergics (benztropine, trihexyphenidyl) — these do NOT help TD and may worsen it. (4) The physician will likely reduce the antipsychotic to the lowest effective dose or switch to an atypical antipsychotic (which carries lower TD risk). (5) Educate the client and family about the movements and their cause. (6) Explain that these movements may persist even after medication changes — preparing the client and family for this possibility. (7) Continue regular AIMS assessments to monitor progression. Key teaching: Prevention is the most important strategy — regular AIMS assessments should have been occurring throughout the years of fluphenazine therapy.

All NMS criteria are met: hyperthermia (40.8°C), lead-pipe rigidity, autonomic instability (labile BP, tachycardia, diaphoresis), and altered mental status (confusion) — in a client on haloperidol. Labs confirm rhabdomyolysis (CK 12,000 U/L — normal is <200) and acute kidney injury (creatinine 2.8 mg/dL — normal is 0.6–1.2). Priority interventions in order: (1) STOP HALOPERIDOL immediately per physician's order — this is the single most critical action. (2) Aggressive COOLING: cooling blankets, ice packs to axillae/groin/neck, cool/tepid sponge bath, lower room temperature. Target temperature <38°C. (3) IV FLUIDS: Vigorous hydration (NS or LR) to protect the kidneys from myoglobin deposition (rhabdomyolysis-related AKI). Monitor urine output (target >0.5 mL/kg/hr). (4) DANTROLENE IV: Reduces skeletal muscle rigidity and heat production by inhibiting calcium release. (5) BROMOCRIPTINE: Dopamine agonist that counteracts the dopamine blockade driving NMS. (6) Transfer to ICU for continuous cardiac monitoring, respiratory support if needed, and frequent vital signs. (7) Monitor renal function, CK, electrolytes. (8) Document everything with precise timestamps. NOTE: Benztropine is NOT indicated for NMS — this is a common NLE distractor.